Shattuck Labs (NASDAQ:STTK - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.01, Zacks reports. Shattuck Labs had a negative return on equity of 61.92% and a negative net margin of 1,156.46%.
Shattuck Labs Stock Performance
NASDAQ:STTK traded down $0.10 during mid-day trading on Monday, hitting $0.95. The company had a trading volume of 97,539 shares, compared to its average volume of 377,186. Shattuck Labs has a fifty-two week low of $0.94 and a fifty-two week high of $11.76. The firm has a market cap of $45.36 million, a P/E ratio of -0.62 and a beta of 1.66. The business's fifty day moving average is $1.24 and its two-hundred day moving average is $1.44.
Analyst Upgrades and Downgrades
Several analysts recently commented on STTK shares. Needham & Company LLC reaffirmed a "hold" rating on shares of Shattuck Labs in a research note on Thursday. Leerink Partners began coverage on shares of Shattuck Labs in a report on Monday, March 17th. They issued an "outperform" rating and a $4.00 target price on the stock. Leerink Partnrs raised shares of Shattuck Labs to a "strong-buy" rating in a report on Monday, March 17th. Finally, HC Wainwright reaffirmed a "neutral" rating on shares of Shattuck Labs in a report on Thursday. Four equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $7.50.
View Our Latest Report on Shattuck Labs
Shattuck Labs Company Profile
(
Get Free Report)
Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.
See Also
Before you consider Shattuck Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Shattuck Labs wasn't on the list.
While Shattuck Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
